Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Apr;36(4):856–859. doi: 10.1128/aac.36.4.856

Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

S K Spangler 1, M R Jacobs 1, P C Appelbaum 1
PMCID: PMC189460  PMID: 1323956

Abstract

The MICs of four new quinolones, sparfloxacin (AT-4140, CI-978), PD 131628 (the active form of the prodrug CI-990), temafloxacin, and Win 57273, compared with those of ciprofloxacin and ofloxacin were tested against 53 penicillin-susceptible, 35 penicillin intermediate-resistant, and 51 penicillin-resistant pneumococci. Susceptibility to RP 59500, a new streptogramin, was also tested and compared with those to the quinolones, erythromycin, and vancomycin. All MICs were determined by a standardized agar dilution method by using Mueller-Hinton agar supplemented with sheep blood. Quinolone, vancomycin, and RP 59500 susceptibilities were not affected by susceptibility or resistance to penicillin. For Win 57273, the MICs for 50% (MIC50) and 90% (MIC90) of strains tested were 0.015 and 0.03 micrograms/ml, respectively. MIC50S of both sparfloxacin and PD 131628 were 0.25 micrograms/ml, and MIC90S were 0.5 micrograms/ml. The MIC50 of temafloxacin was 0.5 micrograms/ml, and the MIC90 was 1.0 micrograms/ml. By comparison, ofloxacin and ciprofloxacin both yielded MIC50S of 1.0 micrograms/ml and MIC90s of 2.0 micrograms/ml. RP 59500 yielded an MIC50 of 0.5 microgram/ml and an MIC90 of 1.0 microgram/ml and was only 1 doubling dilution less active against 17 erythromycin-resistant strains. Vancomycin was active against all strains (MIC50, 0.25 microgram/ml; MIC90, 0.5 microgram/ml). All four experimental quinolones as well as RP 59500 show promise for therapy of infections with penicillin-resistant and -susceptible pneumococci.

Full text

PDF
856

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C., Spangler S. K., Crotty E., Jacobs M. R. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones. J Antimicrob Chemother. 1989 Apr;23(4):509–516. doi: 10.1093/jac/23.4.509. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol. 1987 Aug;6(4):367–377. doi: 10.1007/BF02013089. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J Antimicrob Chemother. 1989 Apr;23(4):527–535. doi: 10.1093/jac/23.4.527. [DOI] [PubMed] [Google Scholar]
  4. Bitar N., Claes R., Van der Auwera P. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother. 1989 Oct;33(10):1686–1690. doi: 10.1128/aac.33.10.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Domagala J. M., Heifetz C. L. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991 Jan;35(1):141–146. doi: 10.1128/aac.35.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  7. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eliopoulos G. M., Klimm K., Rice L. B., Ferraro M. J., Moellering R. C., Jr Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother. 1990 Jun;34(6):1154–1159. doi: 10.1128/aac.34.6.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fass R. J. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1991 Mar;35(3):553–559. doi: 10.1128/aac.35.3.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gombert M. E., Aulicino T. M. Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin. Antimicrob Agents Chemother. 1984 Dec;26(6):933–934. doi: 10.1128/aac.26.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Granneman G. R., Carpentier P., Morrison P. J., Pernet A. G. Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrob Agents Chemother. 1991 Mar;35(3):436–441. doi: 10.1128/aac.35.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
  14. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Isaacs D., Slack M. P., Wilkinson A. R., Westwood A. W. Successful treatment of Pseudomonas ventriculitis with ciprofloxacin. J Antimicrob Chemother. 1986 Apr;17(4):535–538. doi: 10.1093/jac/17.4.535. [DOI] [PubMed] [Google Scholar]
  16. Jones R. N., Barry A. L. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990 Feb;34(2):306–313. doi: 10.1128/aac.34.2.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kaatz G. W., Seo S. M. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob Agents Chemother. 1990 Jul;34(7):1376–1380. doi: 10.1128/aac.34.7.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Klugman K. P. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990 Apr;3(2):171–196. doi: 10.1128/cmr.3.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Landesman S. H., Cummings M., Gruarin A., Bernheimer H. Susceptibility of multiply antibiotic-resistant pneumococci to the new beta-lactam drugs and rosaramicin. Antimicrob Agents Chemother. 1981 Apr;19(4):675–677. doi: 10.1128/aac.19.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mazzulli T., Simor A. E., Jaeger R., Fuller S., Low D. E. Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990 Mar;34(3):467–469. doi: 10.1128/aac.34.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McClain J. B., Rhoads J., Krol G. Cerebrospinal fluid concentrations of ciprofloxacin in subjects with uninflamed meninges. J Antimicrob Chemother. 1988 Jun;21(6):808–809. doi: 10.1093/jac/21.6.808. [DOI] [PubMed] [Google Scholar]
  23. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nye K., Shi Y. G., Andrews J. M., Ashby J. P., Wise R. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother. 1989 Sep;24(3):415–424. doi: 10.1093/jac/24.3.415. [DOI] [PubMed] [Google Scholar]
  25. Raoof S., Wollschlager C., Khan F. Treatment of respiratory tract infections with ciprofloxacin. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):139–145. doi: 10.1093/jac/18.supplement_d.139. [DOI] [PubMed] [Google Scholar]
  26. Sedlock D. M., Dobson R. A., Deuel D. M., Lesher G. Y., Rake J. B. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother. 1990 Apr;34(4):568–575. doi: 10.1128/aac.34.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tweardy D. J., Jacobs M. R., Speck W. T. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis. J Antimicrob Chemother. 1983 Aug;12(2):133–139. doi: 10.1093/jac/12.2.133. [DOI] [PubMed] [Google Scholar]
  28. Van Caekenberghe D. L., Pattyn S. R. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother. 1984 Apr;25(4):518–521. doi: 10.1128/aac.25.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ward J. I., Moellering R. C., Jr Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother. 1981 Aug;20(2):204–207. doi: 10.1128/aac.20.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Watanakunakorn C., Glotzbecker C. Susceptibility of recent clinical isolates of Streptococcus pneumoniae to 17 antibiotics. J Antimicrob Chemother. 1980 Jan;6(1):83–89. doi: 10.1093/jac/6.1.83. [DOI] [PubMed] [Google Scholar]
  31. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES